The company's investment in R&D also suggests a commitment to staying at the forefront of the industry, which can provide long-term benefits for investors. Merck spends almost twice on R&D than ...

Merck Animal Health and Eli Lilly and Company have individually announced major US investments totaling more than $1 billion combined, reinforcing their commitments to domestic innovation in ...

R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.

Merck maintained its 2025 full-year revenue ... supported by a robust pipeline and significant investments in manufacturing and R&D. Management emphasized a focus on navigating short-term ...

Merck Animal Health is expanding its ... manufacturing facility and a further $35 million investment in its research and development (R&D) laboratories. The 200,000-square-foot manufacturing ...

The $895 million capital expansion will be constructed on an existing Merck-owned property that is the site of its biologics facility in De Soto, Kansas. It includes an $860 million investment in the ...

Merck’s Life Science segment is strategically positioned to capitalize on robust industry growth, driven by increased R&D investments by pharmaceutical companies. Merck is a leader in thin-film ...

Studney was tasked with leading the company’s R&D recovery ... Studney said. Merck takes a strategic approach to investing in AI. Sometimes it’s a small investment to see how something ...

This latest investment brings Merck's total investment ... Through the expansion of facilities and consolidation of critical R&D activities, Merck aims to accelerate innovation, improve efficiency ...

Merck (NYSE:MRK) recently announced a third-quarter dividend affirmation of $0.81 per share, underscoring its commitment to returning value to shareholders. Over the past week, the company's stock ...